

Correspondence

Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients

DOI: 10.1111/j.1365-2133.2007.08060.x

SIR, Chronic idiopathic urticaria (CIU) is characterized by the occurrence of spontaneous pruritic weals on most days. It is common, but often disabling because of persistent clinical symptoms which negatively influence the quality of life. Antihistamines have been the mainstay of treatment and they produce a good response in most patients, but not in all. For those patients who derive only limited benefit from the initial treatment, therapeutic guidelines advocate the use of antihistamines above the licensed or manufacturers' recommended doses.^{1,2} However, there is scant evidence regarding the effectiveness of dose increases of the same antihistamine in the patients who responded poorly to the first dosage of the agent.

Cetirizine is a second-generation antihistamine effective in treating patients with CIU.³ The manufacturer's recommended dosage is 10 mg daily and it is permissible to increase the dose up to 20 mg daily. As cetirizine inhibits histamine-induced weal and flare reactions dose-dependently,⁴ it is plausible that higher doses of the drug will be more effective in controlling urticarial symptoms. However, the clinical effect

of such dose increases has not been evaluated in patients with CIU. In some previous studies, patients with CIU were initially treated with cetirizine 5 mg, and they were allowed to increase the dose to 10 or 20 mg if no benefit was obtained at the starting dose.^{5,6} However, neither urticarial activity at each dose nor clinical effects of the dose increase were assessed in these studies. In the present open study, we evaluated the effect of increasing the dose of cetirizine in order to control the disease activity in patients with CIU, who had derived only limited benefit from 10 mg daily of the same drug.

Patients with CIU (> 1 month duration) were recruited from secondary care hospitals. Patients with physical urticaria, or urticaria caused by medications, foods or other known causes were excluded. Prior to the dose-increasing study, patients were treated with cetirizine 10 mg daily for 1 or 2 weeks as a screening period. Twenty-one patients who responded poorly to the treatment, i.e. the change of the total daily score of urticarial symptoms (see below) was less than 1, during the screening period, were enrolled in the study. Approximately one-third of patients who entered the screening period were eligible. At the beginning of the study, patients were randomly assigned to group A (11 patients) or group B (10 patients), after obtaining informed consent, and all patients were given an increased dose of cetirizine, 20 mg daily (10 mg twice daily), for 1 or 2 weeks (period 1). Thereafter,




Fig 1. Mean urticarial activity scores during each observation period. Mean urticarial activity scores for weal, itch, duration and total scores for group A (closed circle) and group B (open circle) during each observation period are shown. ** $p < 0.01$.

patients in group A continued the daily dosage of cetirizine 20 mg, whereas the patients in group B received the decreased dosage of 10 mg, for an additional 1 to 2 weeks (period 2). Patients were instructed to record daily urticarial activity scores throughout the study period including the screening period. The urticarial activity was assessed by using the scoring system as previously described.⁷ Namely, each of the number of weals, the duration of the weals, and the severity of itch, was scored from 0 to 3. The total daily score of the urticarial symptoms, therefore, ranged from 0 to 9. For the assessment of the clinical effect of increase/decrease in the dosage, the data were analysed by the Friedman test and the Steel–Dwass test.

There were no statistically significant differences between the two groups in age (42.5 ± 14.1 vs. 36.9 ± 16.7 years, mean $\pm$ SD, for groups A and B, respectively) or mean urticarial activity scores during the screening period [weal scores 1.09 ± 0.78 vs. 1.11 ± 0.64 , itch scores 1.53 ± 0.89 vs. 1.56 ± 0.64 , duration scores 1.21 ± 0.96 vs. 1.66 ± 1.14 and total scores 3.84 ± 1.76 vs. 4.49 ± 2.02 (Mann–Whitney test)]. All patients had been unsatisfactorily treated with H_1 -receptor antagonists, such as loratadine, fexofenadine, olopatadine or hydroxyzine, with or without corticosteroids. The numbers of previously used drugs were also not significantly different (2.90 ± 1.37 vs. 3.09 ± 1.92). These medications were ceased before the screening period in each patient. Two patients in group A had received montelukast 10 mg daily before the study, and they received the same dose of the agent throughout the study. As shown in Figure 1, urticarial activity scores in period 1 were significantly lower than those in the screening period in both groups, indicating the effect of dose increases in controlling the symptoms. In group A, urticarial activity scores improved further in period 2. On the other hand, in group B, urticarial activity scores of weal, itch and total in period 2 were higher than those in period 1 and weal and itch scores in period 2 were not significantly different from those in the screening period.

It is known that urticarial activity is usually higher during the early stages in each patient and tends to remit with time. It is thus possible that spontaneous resolution of the disease may affect the study. However, the exacerbation after the decrease of cetirizine observed in group B indicates that the improvement observed in this study is due to dose increment rather than spontaneous resolution. In addition, our results indicate that the continuation of effective doses of cetirizine may lead to further improvement as shown in group A. Concerning adverse effects, two patients in group B complained of drowsiness in period 1, but their complaints disappeared after the decrease of dosage of cetirizine

in period 2. Otherwise adverse effects were not observed throughout the study period in all subjects. Although the observation periods of 1–2 weeks could be short for evaluating this fluctuating disease and we could not deny the possible involvement of placebo effect in this study, our results indicate the clinical usefulness of a dose increase of cetirizine.

In conclusion, our results support the clinical impressions⁸ that dose increases of antihistamines may lead to better control of urticarial activity in patients who have not responded well to initial doses of the same drug, and that the continuation of the effective dose leads to further improvement of the disease severity. For more robust evidence, a longer double-blinded study is indicated and other H_1 antagonists should be studied in a similar fashion.

Department of Dermatology, Division of Molecular
Medical Science, Programs for Biomedical Research,
Graduate School of Biomedical Sciences, Hiroshima
University, 1-2-3, Kasumi, Minami-ku,
Hiroshima 734-8551, Japan
*Division of Dermatology, Hiroshima City Asa
Hospital, Hiroshima, Japan
E-mail: kameyosi@hiroshima-u.ac.jp

Y. KAMEYOSHI
T. TANAKA
S. MIHARA
S. TAKAHAGI
N. NIIMI*
M. HIDE

References

- Grattan C, Powell S, Humphreys F. Management and diagnostic guidelines for urticaria and angio-oedema. *Br J Dermatol* 2001; **144**:708–14.
- Zuberbier T, Bindslev-Jensen C, Canonica W et al. EAACI/GA2LEN/EDF guideline: management of urticaria. *Allergy* 2006; **61**:321–31.
- Slater JW, Zechin AD, Haxby DG. Second-generation antihistamines: a comparative review. *Drugs* 1999; **57**:31–47.
- Ramboer I, Bumbacea R, Lazarescu D, Radu JR. Cetirizine and loratadine: a comparison using the ED50 in skin reactions. *J Int Med Res* 2000; **28**:69–77.
- Kalivas J, Breneman D, Tharp M et al. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. *J Allergy Clin Immunol* 1990; **86**:1014–18.
- Tharp MD. Cetirizine: a new therapeutic alternative for chronic urticaria. *Cutis* 1996; **58**:94–8.
- Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. *Arch Dermatol Res* 2005; **297**:134–8.
- Cheung ST, Tucker W. Nonsedating antihistamines in the treatment of severe chronic idiopathic urticaria: are they used optimally? *Br J Dermatol* 2006; **154**:1012–13.

Conflicts of interest: none declared.